NIOX GroupCSSPF 77 EV-to-EBITDA is 14.68 as of Jul. 06, 2026. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 512 Medical Devices & Instruments companies, NIOX Group ranks worse than 51.76% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, NIOX Group's enterprise value is $302.85 Mil.
NIOX Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $20.63 Mil. Therefore, NIOX Group's EV-to-EBITDA for today is 14.68.
The historical rank and industry rank for NIOX Group's EV-to-EBITDA or its related term are showing as below:
CSSPF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -18.2 Med: -0.51 Max: 63.58
Current: 14.77
During the past 13 years, the highest EV-to-EBITDA of NIOX Group was 63.58. The lowest was -18.20. And the median was -0.51.
CSSPF's EV-to-EBITDA is ranked worse than 51.76% of 512
companies
in the Medical Devices & Instruments industry
Industry Median: 14.495
vs CSSPF: 14.77
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
NIOX Group (OTCPK:CSSPF) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
NIOX Group's share price for today is $0.75.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NIOX Group's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.022.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for NIOX Group's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NIOX Group's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NIOX Group EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NIOX Group's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where NIOX Group's EV-to-EBITDA falls into.
NIOX Group's current Enterprise Value is $302.85 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. NIOX Group's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $20.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group (CSSPF) has a EV-to-EBITDA of 14.68 as of Jul. 06, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NIOX Group. According to the industry distribution chart, NIOX Group ranks #265 out of 512 companies in the Medical Devices & Instruments industry, placing it in the top 51.8%.
Is NIOX Group's EV-to-EBITDA too high?
NIOX Group's current EV-to-EBITDA is 14.68. The Medical Devices & Instruments industry median EV-to-EBITDA is 14.50. NIOX Group's value of 14.68 is 1.3% above this industry median. Based on the distribution chart, NIOX Group ranks #265 out of 512 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #265 out of 512 companies for EV-to-EBITDA. This places NIOX Group in the lower half of its industry. The industry median EV-to-EBITDA is 14.50. NIOX Group's value of 14.68 is 1.3% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.50, based on 512 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current EV-to-EBITDA of 14.68 is 1.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on NIOX Group. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current EV-to-EBITDA is 14.68. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.75 — trading 38% below its estimated fair value. The current EV-to-EBITDA is 14.68 and 1.3% above the Medical Devices & Instruments industry median of 14.50. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For NIOX Group (CSSPF), the current EV-to-EBITDA is 14.68 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.75 is trading 38% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
EV-to-EBITDA: 14.68
GF Value™: $1.21 vs. price of $0.75 (38% below fair value)
Industry Position: 1.3% above the Medical Devices & Instruments median (#265 of 512)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
